Skip to content

Functional Cure (Chronic Viral Infection)

Recognize sustained disease-specific control of a chronic viral infection without claiming that every persistent viral source has been eliminated.

Version
v2 · 2026-10-03 · History
Domain-specific #
13256
Domain group
Applied Sciences & Engineering
Origin domain
Medicine & Healthcare
Subdomains
Infectious Disease, Virology → Medicine & Healthcare

Core Idea

A functional cure in chronic viral infection is a declared endpoint of sustained disease control without requiring proof that every source of the virus has been eliminated. The claim has two parts that must be kept separate: a disease-specific pattern of virological or antigen findings that warrants the word control, and an eradication claim that remains unmade. It must also state the treatment context and observation period. For HIV, an ART-free remission goal concerns durable viral control without ordinary antiretroviral therapy; NIH distinguishes that goal from the classical cure of eliminating all virus-carrying cells. For chronic hepatitis B (HBV), an original cohort study uses functional cure for sustained virological response and disappearance of hepatitis B surface antigen (HBsAg) after finite treatment. These are applications of the same endpoint distinction, not the same laboratory criterion.[1][2][3]

“Functional” marks what has been achieved in a specified disease context, not a universal mechanism or a guarantee of permanence. Some HIV post-treatment controllers in the VISCONTI study maintained years of control despite a very low persisting reservoir. In the HBV cohort, intrahepatic cccDNA was detected in 35 of 48 participants classified as functionally cured and was not detected by the study assay in 13; the latter result is not proof that all viral material was absent. Persistent sources can therefore be demonstrated in some cases, possible in others, and undecided by a negative assay. Recurrence is a possibility, not a necessary outcome for every person.[2][3]

Structural Signature

Sig role-phrases: chronic viral condition — declared control endpoint — specified therapy context — eradication comparator — persistence uncertainty — durability qualification.

  • Chronic viral condition. The bearer is an infection whose observed activity and underlying viral persistence need not track each other exactly. HIV and HBV have different biology, so their markers are not substitutable.[2][3]
  • Declared control endpoint. The claim states the disease's recognized markers and a sustained observation interval. VISCONTI describes post-ART viremia control; Gan and colleagues use HBsAg disappearance together with virological response. A single negative test is not the full relation.[2][3]
  • Specified therapy context. The claim says what ordinary suppression is absent or what finite prior course frames the observation. ART-free HIV remission is not necessarily intervention-free: NIH also discusses intermittent or continual non-ART interventions as possible routes to that goal. This role describes evidence, not an instruction to change care.[1]
  • Eradication comparator. Functional success is contrasted with a stronger assertion that all relevant viral sources are gone. NIH states that classical HIV cure requires eliminating virus-carrying cells; Gan and colleagues separately describe stronger HBV complete/sterile-cure concepts.[1][3]
  • Persistence uncertainty. A measured reservoir can coexist with control, while a nondetection has an assay limit. It is not constitutive that persistence be demonstrated in every individual.[2][3]
  • Durability qualification. Sustained is bounded by observed follow-up. Subsequent marker recurrence can change an endpoint judgment; it is not built into the definition that recurrence must occur.[2][3]

What It Is Not

It is not a synonym for sterilizing or classical cure. HIV plasma control does not itself establish elimination of all infected cells; HBV serum HBsAg loss does not itself settle every question about intrahepatic cccDNA or integrated viral DNA. Conversely, one should not require every person labeled functionally cured to have a detectable reservoir: Gan's study reported cccDNA nondetection in 13 of its 48 classified cases. Both “all eliminated” and “all visibly persistent” overstate the observations.[1][3]

It is not ordinary viral suppression during unchanged ongoing standard therapy, nor simply one normal laboratory result. The treatment and follow-up context must be declared. It is also not a single cross-disease test: HIV virological remission and HBV HBsAg/virologic response use different markers. The original chronic-myeloid-leukemia study by Ross and colleagues calls its distinct endpoint treatment-free molecular remission, not the identical HIV/HBV functional-cure assay. Its analogy is worth studying, but this entry does not silently absorb it.[2][3][4]

This is a descriptive endpoint distinction, not a protocol for stopping medicine, evaluating an individual patient, or predicting their course.

Scope of Application

The entry applies where chronic viral-infection researchers explicitly distinguish sustained disease control from proof of total viral-source elimination. The VISCONTI investigators use functional HIV cure as a goal while reporting a selected group of post-treatment controllers who had long-term virological remission after prior ART. NIH's later institutional statement frames sustained ART-free HIV remission as an alternative goal to classical eradication; some strategies might use non-ART interventions, so the scope cannot be reduced to “all treatment stopped.”[2][1]

In chronic HBV, Gan and colleagues use functional cure for a disease-specific sustained response with HBsAg disappearance after a finite course, contrasting it with stronger complete or sterile-cure claims. Their cohort illustrates the difference between a serum-defined endpoint and questions about intrahepatic persistence. The reported follow-up and assay methods bound the interpretation. Neither the HIV cohort nor the HBV cohort supplies a universal population frequency, treatment recommendation, or marker threshold transferable to the other infection.[3][2]

Clarity

The abstraction resolves an equivocation in the word cure. One question is whether infection is controlled to a specified functional endpoint; another is whether its biological source has been eliminated. Control can be observed without answering the second question. That distinction is necessary in HIV because a low reservoir can remain compatible with long off-ART control, and in HBV because serum HBsAg loss can coexist with detectable intrahepatic cccDNA in some observed participants.[2][3]

It also separates absence of the ordinary suppressive regimen from absence of every intervention. NIH expressly allows potential ART-free remission approaches that involve other interventions. Finally, it separates marker recurrence from virological relapse: Gan and colleagues observed seven HBsAg seroreversions, but only two virological relapses in that reported cohort. These distinctions keep a bounded endpoint from becoming a claim of eradication or an inevitable rebound forecast.[1][3]

Manages Complexity

Chronic viral-disease reports contain different measurements, tissues, treatment histories and follow-up windows. Functional cure reduces the comparison to a manageable set of questions: Which infection? Which control markers? For how long? Under what therapy context? What stronger eradication claim is withheld? The questions travel; their answers do not. HIV plasma RNA and reservoir observations fill different slots from HBV serum HBsAg, serum DNA and intrahepatic cccDNA.[2][3]

This compression prevents two opposite errors. Requiring proof about every hidden compartment before acknowledging any useful control endpoint erases a meaningful research outcome. Equating a favorable serum test with total viral elimination overpromises. A role-based account preserves both the reported success and its unresolved biological limits.[1][3]

Abstract Reasoning

When reading a functional-cure claim, first identify whether the evidence establishes a control endpoint or a sterilizing endpoint. Then read the specified marker and follow-up statement in its own disease. For example, VISCONTI's long-term post-ART control supports the former in that selected HIV group; its low residual reservoir is direct reason not to infer the latter. In Gan's HBV cohort, HBsAg disappearance and sustained response support the authors' functional classification, while cccDNA detection in 35 participants prevents a blanket eradication inference.[2][3]

The abstraction also disciplines counterfactuals. If only one favorable test exists, durability has not been shown. If observed control depends on continuing ordinary suppression, it does not instantiate the off-standard-treatment endpoint in these original sources. If later recurrence occurs, the earlier bounded report must be qualified; if no recurrence has been seen, one cannot infer that recurrence is impossible. These are rules for interpreting published evidence, not for directing care.[1][3]

Knowledge Transfer

The functional-versus-sterilizing distinction transfers within chronic-viral research as a way to phrase goals and evidence limits. HIV and HBV sources both apply the term functional cure to control without a complete-eradication claim. The actual diagnostic markers, mechanisms, observation windows and treatment contexts remain disease-specific. A copied threshold would not be knowledge transfer; it would be a category error.[2][3]

CML treatment-free molecular remission shows a structural analogy: control may be observed under a different treatment context despite detectable residual disease in some studied people. Ross and colleagues use their own molecular criteria and terminology, however. The presence of a similar outcome-versus-elimination contrast does not establish that their patients meet either viral definition or that functional cure is a validated literal alias for CML treatment-free remission.[4]

Examples

HIV post-treatment control. VISCONTI reported 14 selected post-treatment controllers whose viremia remained controlled for several years after ART that had begun early in infection. Their HIV reservoir was extremely low and could remain measurable; the authors present the finding as relevant to a functional-cure goal, not proof of viral eradication. This observation must not be turned into a general care prediction.[2] Mapped back: chronic viral condition = HIV; declared endpoint = years of viremia control; therapy context = no ordinary ART during the reported control; eradication comparator = NIH's elimination-of-all-virus-carrying-cells criterion was not shown; persistence uncertainty = low measured reservoir in the original group; durability = years observed, not guaranteed permanence.

Chronic HBV functional-cure cohort. Gan and colleagues classified 48 participants by their study's sustained HBsAg/virological-response endpoint after finite treatment. Intrahepatic cccDNA was detectable in 35 and not detected in 13 under their assay; seven later had HBsAg seroreversion, including two virological relapses. These observations test what the label does and does not imply within that study, not how another person should be managed.[3] Mapped back: chronic viral condition = HBV; declared endpoint = sustained HBsAg disappearance with virological response; therapy context = finite earlier course and bounded follow-up; eradication comparator = stronger complete/sterile HBV claims were not inferred from serum endpoint alone; persistence uncertainty = heterogeneous cccDNA findings and assay limits; durability = the follow-up period and documented subset recurrence.

Structural Tensions

Meaningful control versus elimination proof. Recognizing a functional endpoint lets a study report durable control without the impossible task of proving every hidden viral source absent. But using the word cure without the explicit distinction can invite an eradication inference the measurements do not support. Reserving every success label for proven elimination avoids that overclaim but conceals a distinct achievable outcome. Diagnostic: Does the report specify the control criteria and explicitly withhold any unsupported eradication conclusion?[1][2][3]

Earlier endpoint recognition versus stronger durability evidence. A finite follow-up can support a bounded sustained-control claim soon enough to report an outcome; longer observation can expose late recurrence and strengthen or revise confidence. One cannot both close a study early and know its long-term trajectory for every participant. Gan's observed seroreversions make that cost concrete without implying that all cases recur. Diagnostic: What observation window does sustained denote here, and would a later marker recurrence change the label or only its durability qualification?[3]

Structural–Framed Character

This entry is framed-leaning but structurally informative. The control-versus-eradication distinction is logically reusable, while the named endpoint's content depends on viral disease, measurement and clinical-research convention.

  • Evaluative weight: substantial. Cure signals an important success, but the entry does not certify that an individual can safely alter treatment or will never relapse; its evaluative force must remain bound to explicit criteria.
  • Human-practice dependence: substantial. Investigators choose assay thresholds, duration and treatment-context definitions, and clinicians interpret consequences; the underlying virus is biological, but the endpoint is a research/clinical classification of observations.[3][1]
  • Institutional origin: material. NIH articulates the HIV ART-free-remission goal; the HBV paper uses a particular study definition. No single institution makes HIV, HBV and CML markers interchangeable.[1][3][4]
  • Vocabulary travel: partial. Control, persistence and eradication can be used across diseases, but ART-free HIV viremia and HBV HBsAg loss are not translations of one assay.[2][3]
  • Import versus recognition: both. The abstract two-endpoint distinction can be recognized in original studies, but applying the label to a new infection imports disease-specific criteria and observation standards; a verbal analogy alone cannot classify a case.

Its character: a domain-framed clinical-research endpoint with a genuine reusable distinction between observed durable control and unproven biological eradication, not a substrate-free prime or a recommendation about treatment.

Structural Core vs. Domain Accent

The structural skeleton is observable durable control under a stated context while a stronger source-elimination proposition remains unproved. This relation recurs in the HIV and HBV papers. The domain accent is constitutive, however: which viral process counts as controlled, what laboratory markers report it, what regimen forms the comparator, and how long an observation is needed differ sharply. The same word cure cannot erase those differences.[2][3]

No compared live prime owns this full skeleton as a necessary parent. Live Stability requires return dynamics after perturbation; a controlled viral state is not thereby shown to be a stable attractor. Maintenance describes preserving function by intervention and may be absent from an observed ART-free control episode. Controlled Reentry requires staged restoration after suspension, not merely infection control. The broader control-versus-eradication relation is an unadmitted future-prime question; this draft remains unparented pending independent DAG review. Its named viral endpoint does not clear the prime bar because the markers, therapy context and evidentiary consequences are indispensable rather than decorative accents.

No strict parent is proposed. Semantic nearness to Stability, Maintenance or Controlled Reentry is insufficient: the first requires restoring dynamics, the second preventive upkeep, and the third monitored staged return. Neither original viral study makes one of those constitutive in every functional-cure case.

Those primes can still help reason about individual cases. A maintenance intervention could be part of some ART-free HIV strategy, but NIH's statement specifically permits different strategies and does not make the prime's maintenance signature a universal component. Whether a new prime should represent the portable outcome-versus-eradication split is reserved for a separate cross-domain review.[1]

Neighborhood in Abstraction Space

Functional Cure (Chronic Viral Infection) sits in a sparse region of the domain-specific corpus (90th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Clinical Trial Design & Drug Safety (22 abstractions)

Nearest neighbors

Computed from structural-signature embeddings · 2026-10-08

Not to Be Confused With

HIV remission was the frozen Wikipedia request; Functional Cure (Chronic Viral Infection) is the staged reframe. The request is not made a blanket alias because HIV remission can be used with different treatment and duration qualifiers, and the draft also covers HBV. Any eventual alias decision must check exact scope. CML treatment-free molecular remission remains a distinct terminology/identity question, not an added recognized variant.[4]

Do not read “functional” as “virus absent,” “all disease risks gone,” “off every possible intervention,” or “rebound inevitable.” The original sources support none of those universal implications. In the HBV study, cccDNA nondetection is assay-bounded, and seven HBsAg seroreversions are not identical to seven virological relapses. This distinction is descriptive scholarship and cannot adjudicate a person's treatment or prognosis.[1][3]

References

[1] National Institutes of Health / NIAID, “Fauci: HIV remission free of antiretroviral therapy is a feasible goal”, 25 July 2018, original institutional statement contrasting classical cure with sustained ART-free remission and noting possible non-ART interventions. The indexed original HTML was inspectable; direct page open was intermittently unavailable. registry ↩a ↩b ↩c ↩d ↩e ↩f ↩g ↩h ↩i ↩j ↩k ↩l ↩m

[2] Asier Sáez-Cirión et al., “Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy: ANRS VISCONTI Study”, PLoS Pathogens 9 (2013), e1003211, original abstract and Figures 1, 4 and 5 (DOI 10.1371/journal.ppat.1003211). The reported group is selected and does not establish a general patient outcome. registry ↩a ↩b ↩c ↩d ↩e ↩f ↩g ↩h ↩i ↩j ↩k ↩l ↩m ↩n ↩o ↩p ↩q

[3] Weiqiang Gan et al., “Reduction in Intrahepatic cccDNA and Integration of HBV in Chronic Hepatitis B Patients with a Functional Cure”, Journal of Clinical and Translational Hepatology 11 (2023), original Abstract, Introduction, Results Table 1 and follow-up results. “Not detected” refers to the study assay, not proof of biological absence. registry ↩a ↩b ↩c ↩d ↩e ↩f ↩g ↩h ↩i ↩j ↩k ↩l ↩m ↩n ↩o ↩p ↩q ↩r ↩s ↩t ↩u ↩v ↩w ↩x ↩y

[4] David M. Ross et al., “Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells”, Leukemia 32 (2018), original publisher abstract, DOI 10.1038/s41375-018-0264-0. Cited only as a terminology/endpoint comparator, not as direct evidence for HIV or HBV. registry ↩a ↩b ↩c ↩d